OK I will play the guessing game

I say 14th August. I think on the balance of probabilities we get favourable differences from placebo vs ADAScog in E4 carriers mITT at 1.6 points, and in E4 noncarriers at 2.5 points (two doses combined with no dose response measurable) overall population. The study will be just P<0.05 in E4 and P<0.01 in E4-. Functional scales will favour drug but trend only. Biomarkers will run as expected with 25% PIB PET clearance in both APOE genotypes, P-tau will be reduced highly significant in treated groups. Abeta in CSF will not change. MRI in will show reduced hippocampal atrophy and reduced increase in ventricular volume in treated arms.